Vivos Therapeutics Receives Groundbreaking FDA 510 ( k ) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea ( OSA ) market with new FDA clearance and new strategic marketing and distribution model ...
| Ticker |
Sentiment |
Impact |
|
VVOS
|
Neutral
|
9 %
|
|
NHPEF
|
Somewhat Bullish
|
2 %
|
